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Abstract: Gout is an inflammatory arthritis characterized by abrupt self-limiting attacks of 
inflammation caused by precipitation of monosodium urate crystals (MSU) in the joint. Recent 
studies suggest that orchestration of the MSU-induced inflammatory response is dependent on 
the proinflammatory cytokine IL-1β, underlined by promising results in early IL-1 inhibitor 
trials in gout patients. This IL-1-dependent innate inflammatory phenotype, which is observed 
in a number of diseases in addition to gout, is now understood to rely on the formation of the 
macromolecular NLRP3 inflammasome complex in response to the MSU ‘danger signal’. 
This review focuses on our current understanding of the NLRP3 inflammasome and its critical 
role in MSU-crystal induced inflammatory gout attacks. It also discusses the management of 
treatment-resistant acute and chronic tophaceous gout with IL-1 inhibitors; early clinical studies 
of rilonacept (IL-1 Trap), canakinumab (monoclonal anti-IL-1β antibody), and anakinra have 
all demonstrated treatment efficacy in such patients.
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Introduction
Gout is one of the oldest recognized afflictions in humans, with a documented history 
reaching back to the Egyptians in 2640 BC. Described by Hippocrates as the ‘arthritis 
of the rich’ due to its association with food and alcohol, gout is an inflammatory arthri-
tis caused by precipitation of monosodium urate (MSU) in articular joints and bursal 
tissues of individuals with hyperuricemia and is characterized by abrupt, self-limiting 
attacks of joint inflammation. Although MSU was identified in gout in the 1700s1 and 
shown to be the causative agent in 1899,2 the mechanisms by which MSU crystals 
trigger acute inflammation have only recently begun to be understood.
Proinflammatory cytokines undoubtedly have a critical role in orchestrating the 
inflammatory reaction to MSU crystals. Recent studies have implicated interleukin-1β 
(IL-1β) as a key regulatory proinflammatory cytokine in gout, promoting a neutro-
phil influx into the synovium and joint fluid that is the pathological hallmark of an 
acute inflammatory attack.3 Compelling evidence for IL-1β’s role in gout-associated 
pain and inflammation is provided by studies in both animals and man. In a murine 
gout model, inflammation following MSU injection into the mouse ankle joint was 
significantly reduced both in mice deficient for the IL-1 receptor and in wildtype 
mice treated with the IL-1 inhibitor IL1 Trap (rilonacept).4,5 In clinical studies, a 
rapid response was observed in patients with acute gouty arthritis following treat-
ment with a number of anti-IL-1 agents (IL-1RA [anakinra], IL-1Trap, and anti-IL-1β 
monoclonal antibody [canakinumab]) thereby reinforcing the argument for a pivotal 
Journal of Inflammation Research 2011:4submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
40
Kingsbury et al
role for IL-1β in gout pathogenesis.6–8 It is currently unclear 
whether IL-1α is also involved in gout pathogenesis since 
early IL-1  inhibitors (anakinra and rilonacept) inhibit both 
members of the IL-1 family; however the rapid and sustained 
response of gout patients to canakinumab in a recent Phase II 
study9 suggests that IL-1β may be the more essential of the 
two IL-1 cytokines.
IL-1β is produced as an inactive pro-molecule by 
immune cells, including macrophages, monocytes, and 
dendritic cells, following immune stimulation and is then 
cleaved to its active, p17 form by caspase-1 (also termed 
IL-1-converting enzyme or ICE), itself existing as a pro-
form until the initiation of the innate immune response. The 
mechanism of caspase-1 and IL-1β activation  following 
MSU deposition has been the focus of a number of recent 
high profile studies and is now understood to involve the 
formation of macromolecular complexes termed ‘inflam-
masomes’. Since its discovery less than a decade ago, 
the NLRP3 inflammasome complex has been implicated 
as a key regulator of the innate inflammatory phenotype 
of several diseases, including gout and type 2 diabetes. 
In addition, mutations in NLRP3  inflammasome com-
ponents have been shown to be responsible for the dys-
regulated IL-1β production observed in a number of (auto)
inflammatory disorders, including Muckle–Wells syndrome 
(MWS),  familial cold autoinflammatory syndrome (FCAS), 
and chronic infantile neurologic, cutaneous, and articular 
 syndrome/neonatal onset multisystem inflammatory disease 
(CINCA/NOMID).
In this review we discuss the mechanisms and pathophysi-
ology of the inflammasome complex and, in particular, its 
role in mediating the innate immune inflammatory response 
to MSU crystal deposition in gout.
Structure and molecular  
mechanisms involved  
in inflammasome activation
The innate immune system is characterized by its ability to 
recognize and respond to an array of pathogens (including 
viruses, bacteria, and fungi) and to endogenous molecules 
released by host cells as a result of necrosis, infections, 
membrane,10 and lysosomal11,12 damage, injury, or certain 
pathological conditions (including mammalian dsDNA, 
extracellular ATP, and MSU crystals),13–16 through detection 
of pathogen-associated and danger-associated molecular 
patterns (PAMPS and DAMPs respectively). This response 
is mediated by germline-encoded receptors termed pattern-
recognition receptors (PRRs).
Among the PRR families that have been described to 
date include the Toll-like receptors (TLRs), which are 
associated with extracellular (TLRs 1, 2, 5, 6, and 10) 
or endosomal (TLRs 3, 7, 8, and 9) membranes and the 
intracellular RIG-like helicases (RLHs) and NOD-like 
receptors (NLRs). TLRs, of which there are 10 known in 
humans (TLR 1-10) and 12 in mice (TLR 1-9 and 11-13), 
are type 1 transmembrane proteins composed of three 
major domains and characterized by leucine-rich repeats 
(LRRs) in the ectodomain which mediate PAMP/DAMP 
recognition. TLRs are expressed on many cell types and 
are known to respond to a variety of PAMPs and DAMPs, 
including bacterial DNA,13 lipopolysaccharide (LPS),16 
peptidoglycan,17 teichoic acids,17 flagellin18 pilin,19,20 viral 
dsRNA,21 and fungal zymosan.22 Upon activation they 
differentially trigger signaling cascades that mediate 
production of the transcription factors NF-κβ, AP-1, and 
interferon-regulatory factor (IRF)-3, which, in turn, mediate 
transcription of proinflammatory cytokines, such as inter-
leukins, interferons, and TNF, that drive the inflammatory 
response. The TLRs have been the subject of extensive 
investigation and review over recent years and will therefore 
not be discussed in depth in this review. The two known 
RLHs, RIG-1 and MDA5, are viral RNA sensors which, 
upon stimulation, activate NF-κB and IRF3/7 leading to 
transcription of type I interferons.23
The intracellular NLRs, like TLRs, are capable of recog-
nizing both PAMPs and DAMPs, and have become a focal 
point for investigation of the immune response to foreign 
agonists and endogenous molecules. Known activators of 
the NLRs include bacterial muramyl dipeptide (MDP),24 
microbial toxins (such as alpha hemolysin of Staphylococcus 
aureus),25 RNA of bacterial and viral origin,26,27 MSU and 
calcium pyrophosphate dihydrate (CPPD) crystals,15 alum,28 
asbestos,29,30 silica,29,30 and extracellular ATP14 (Table 1). To 
date, at least 23 human and 34 murine NLR genes have been 
identified, although the physiological functions of many 
of these are still poorly understood.31 NLRs are character-
ized by three domains: a C-terminal LRR ‘sensor’ domain, 
a central nucleotide-binding domain (NOD, also called 
NACHT domain) which regulates self-oligomerization and 
an N-terminal interaction domain which mediates protein–
protein interactions with downstream signaling intermedi-
ates (Figure 1). The N-terminal domain can also be used to 
categorize the NLRs into 5 subfamilies: NLRA (containing 
an acidic transactivation domain), NLRB (containing a 
baculovirus inhibitor of apoptosis protein repeat [BIR]), 
NLRC (containing a caspase-recruitment domain [CARD]), 
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Table 1 Inflammasome activators
Inflammasome Stimulus
Whole pathogen PAMP DAMP
NLRP1 MDP
Bacillus anthracis lethal toxin
NLRP3 Staphylococcus aureus
Listeria monocytogenes
Neisseria gonorrhoea
Escherichia coli
Mycobacterium marinum
Candida albicans Influenza A
Adenovirus
Sendai virus
encephalomyocarditis
vaccinia virus
DNA
R837
MDP
LPS
α-toxin
Bacterial RNA
Poly(I:C)
Nigericin
Listeriolysin O
Aerolysin
Maitotoxin
Uric acid
Cholesterol
Asbestos
Silica
Nanoparticles
β amyloid
Hemozoin crystals
Calcium pyrophosphate
dihydrate crystals
Alum
Islet amyloid polypeptide
UvB
Mutations
ATP
Hyaluron
Glucose
NLRP4 (IPAF) Salmonella typhimurium
Shigella flexneri
Legionella pneumophilia
Pseudomonas aeruginosa
vaccinia virus
Mouse cytomegalovirus
Flagellin
AIM2 dsDNA
Abbreviations: DAMP, danger-associated molecular pattern; LPS, lipopolysaccharide; MDP, muramyl dipeptide; PAMP, pathogen-associated molecular pattern; poly(I:C), 
polycytidylic acid.
NLRP (containing a Pyrin domain), and NLRX (containing 
an unknown domain). Of these the best characterized, and the 
most important in the context of this review, are the NLRPs 
and, in particular, NLRP3.
NLRs respond to PAMPs/DAMPs through the formation 
of ‘inflammasomes’; multimeric cytoplasmic protein com-
plexes which act as molecular platforms for the activation 
of inflammatory caspases following stimulation by foreign 
agonists.32 A typical inflammasome is composed of an NLR, 
an adaptor protein such as apoptosis-associated speck-like 
protein containing a CARD (ASC) and an effector caspase 
that activates proinflammatory cytokines, in particular 
IL-1β32 (Figure 1). To date three NLR proteins have been 
identified to form inflammasomes: NLRP1, NLRP3, and 
NLRC4 (also known as IPAF). NLRP3 (NALP3, also 
known as cryopyrin or PYPAF1 [Pyrin-containing Apaf1-
like protein 1]), probably the best understood NLRP, has 
been shown to be involved in the recognition of numerous 
exogenous and host ligands, including bacterial RNA, ATP 
and microbial toxins.33 Stimulation of the NLRP3 LRR 
domain by a foreign agonist is postulated to unfold the 
NLRP3 molecule enabling recruitment of the ASC adaptor 
proteins and  pro-caspase-1. This process of inflammasome 
assembly results in cleavage of pro-caspase-1 to produce 
active caspase-1, which in turn cleaves pro-IL-1β to produce 
IL-1β and also activates IL-18.
Notably no study has yet demonstrated direct interaction 
between the LRRs of NLRs and their respective activators, 
suggesting that indirect mechanisms of sensing and activa-
tion may be involved. Conceptually, given the diverse array 
of molecules now known to activate NLRs it follows that 
additional indirect mechanisms may play a role in mediating 
inflammasome activation. Although the precise molecular 
details have not yet been fully elucidated, current evidence 
points to the potential roles of three signaling pathways in 
mediating agonist recognition and inflammasome  activation. 
Firstly, recent studies suggest a central role for P2X7 
receptor-mediated K+ efflux in NLRP3 activation, with 
prevention of K+ efflux abolishing NLRP3 in response to 
almost all known activators.34–36 Secondly, activation of the 
NLRP3 inflammasome by crystals and particulates appears 
to involve the phagocytic pathway, with particle uptake 
disrupting the phagolysosome acidic compartment and subse-
quent release of capthepsin B.12,37,38 Finally, reactive oxygen 
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 species (ROS) generation has been suggested to be critical 
for inflammasome activation in response to a number of 
stimuli. Inhibition of ROS generation, either through pharma-
cological inhibitors of NAPDH oxidase or siRNA-mediated 
knockdown, prevents IL-1β release in response to MSU and 
a number of other stimuli.29,30 However, the role of ROS is 
still unclear since further studies suggest that increased ROS 
production may actually inhibit caspase-1 activation.39 It is 
conceivable that the mechanisms involved in inflammasome-
activation may differ according to both agonist and cell type. 
A recent study supports this hypothesis, demonstrating that 
whilst IL-1β release by in vitro monocyte cultures required 
only a single exogenous stimulus, two distinct exogenous 
stimuli were required for IL-1β production in macrophage 
cultures.40 The difference between these two cell types is 
understood to be due to the presence of constitutively active 
caspase-1 in monocytes and also the ability of monocytes to 
release endogenous ATP, which can act as a second stimulus 
to trigger IL-1β release. In contrast, macrophages require a 
primary signal to induce transcription and translation and a 
second distinct signal for caspase activation, which leads to 
IL-1β processing and release.
Recently an additional inflammasome sensor was described, 
which triggers caspase-1 and IL-1β cleavage in an ASC-
dependent, NLR-independent manner. The AIM2 inflam-
masome contains a HIN200 domain that binds cytosolic 
DNA, including that of bacterial, viral, and  mammalian 
origin, leading to recruitment of the ASC adaptor protein 
to its PYD and subsequent activation of caspase-1 and 
IL-1β.41–44
Negative regulation of inflammasomes is mediated by 
a family of small proteins composed of a CARD or PYD 
only domain. Five CARD-only proteins have been identi-
fied to date – ICEBERG, Pseudo-ICE, Caspase-12, INCA 
(Inhibitory CARD), and Nod2-S – which, with the exception 
of the Rip2-interacting Nod2-S protein, regulate NLRP3 
activity through interaction with the caspase-1 CARD 
domain, thereby preventing its interaction with other inflam-
masome components.45–48 Two PYD-only proteins, POP1 and 
POP2, interact with ASC or NLRP thereby preventing their 
recruitment into inflammasome complexes. Limited data cur-
rently exist as to how these negative regulators are themselves 
regulated, their different roles in mediating inflammasome 
response and their involvement in inflammatory disease. 
Notably, Caspase-12 deficient mice show increased IL-1β 
secretion49 whilst caspase-12 gene polymorphisms have 
been linked to the modulation of inflammatory and innate 
immune responsiveness.50 In addition to these molecular 
mechanisms of regulation, CD4+ effector and memory 
T-cells were shown to negatively regulate inflammasome 
activity in a CD40L-dependent manner.51 Inhibition of 
the NLRP3 inflammasome was found to be dependent on 
both T-cell activation and antigenic stimulation, suggest-
ing that migration of T-lymphocytes to inflammatory sites 
may provide a feedback loop to regulate the production of 
inflammatory mediators during the later phases of inflam-
matory responses.
Pathophysiology and role  
in various disease states
Inflammasomes are now understood to have a fundamental 
role in the development of autoinflammatory diseases and 
additional roles in infection control, development of immune 
pathologies, and recognition of tissue damage. The last decade 
has seen the emergence of evidence supporting this concept, 
with the first established link to pathological processes pro-
vided by genetic studies of autoinflammatory diseases. Cry-
opyrinopathies (also referred to as hereditary periodic fever 
syndromes or cyropyrin-associated periodic syndromes) form 
a clinical continuum of autoinflammatory disorders charac-
terized by recurrent fevers and  inflammation. Most cases of 
these three disorders (FCAS, MWS, and NOMID in order 
of increasing severity) are now understood to be caused by 
autosomal dominant or de novo gain-of-function mutations in 
NLRP3. Over 40  mutations have been  identified in NLRP352–56 
LRRNACHTPYD
PYDSPRY CC bZIP
PYD
CARD
CARD
CARD
CARD
Caspase-1
Caspase-1
FIIND
Pyrin
CardinalASC
NLRP3
IL-1βpro-IL-1β
Figure 1 The NLRP3 inflammasome complex. The NLRP3 inflammasome complex 
is formed through homotypic interactions between the CARD and PYD domains of 
NLRP3, Pyrin, and ASC. An additional adaptor protein Cardinal is also required to 
facilitate activation of procaspase-1, which in turn cleaves proIL-1β to IL-1β.
Abbreviations: ASC, apoptosis-associated speck-like protein; bZIP, basic leucine 
zipper domain; CARD, caspase activation and recruitment; CC, coiled-coil domain; 
FIIND, domain with a function to find; IL, interleukin; LRR, leucine-rich repeat; 
NACHT, domain present in neuronal apoptosis inhibitor protein (NAIP) major 
histocompatibility complex class II transactivator; NLRP3, NACHT domain, LRR 
domain, and Pyrin domain-containing protein; PYD, Pyrin domain; SPRY, SPRY 
domain.
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each producing a constitutively active form of NLRP3, most 
likely due to spontaneous NLRP3 oligomerization, and hence 
elevated levels of secreted IL-1β, which drive the inflam-
mation. In keeping with this, gene-targeted mice harboring 
mutations equivalent to those found in MWS exhibit hyper-
active NLRP3  inflammasomes leading to elevated IL-1β.57 
This discovery has revolutionized the clinical management 
of these diseases, with patients responding well to IL-1β 
antagonism, for example by anakinra,58–60 next-generation 
IL-1β antagonists,61–65 or caspase-1 inhibitors.66
Two additional autoinflammatory diseases, familial 
Mediterranean fever (FMF) and pyogenic arthritis, pyoder-
magangrenosum, and acne (PAPA) are also caused by muta-
tions in the inflammasome pathway; FMF by mutations in 
the Pyrin-encoding MEFV gene67 and the syndrome of PAPA 
by mutations in the gene encoding proline-serine-threonine-
phosphatase-interacting protein (PSTPIP1), which binds 
Pyrin through its Src-homology-3 domain.68,69 Genetic vari-
ants in NLRP3 and other inflammasome-related genes have 
also been related to susceptibility and disease severity in a 
number of other chronic inflammatory disorders, including 
rheumatoid arthritis,70,71 Crohn’s disease,72 gout,73 and the 
recently identified deficiency of the interleukin-1-receptor 
antagonist (DIRA).74
In addition to causal mutations in the NLRP3 inflam-
masome pathway, the pathology of a number of inflammatory 
diseases has been linked to the activation of this inflam-
masome by disease-specific inflammasome agonists. For 
example, the fibrillar peptide amyloid-β, which accumulates 
to form the senile plaques responsible for the pathogenesis 
of Alzheimer’s disease,37 is now known to be an inflam-
masome activator. Studies suggest that NLRP3, caspase-1, 
and IL-1β are essential for the recruitment of microglia 
to exogenous amyloid-β in the brain and for microglial 
synthesis of proinflammatory and neurotoxic factors, indi-
cating a critical role for the inflammasome pathway in the 
innate immune response to amyloid-β and the subsequent 
tissue damage that is the hallmark of Alzheimer’s disease. 
In type 2 diabetes, islet amyloid polypeptide, which forms 
amyloid deposits in the pancreas, activates NLRP3, result-
ing in IL-1β release and inducing apoptosis of pancreatic 
beta cells75 whilst cholesterol crystals have been shown 
to trigger inflammasome activation in atherosclerosis.76,77 
Late-stage human melanoma cells exhibit autoinflammatory 
characteristics, spontaneously secreting active IL-1β due 
to constitutive assembly and activation of NLRP3.78 IL-1 
mediated autoinflammation drives macrophage chemotaxis 
and angiogenesis, thereby directly contributing to disease 
development and progression.78 The inflammasome has also 
been linked to the progression of chronic kidney disease79 
and to a number of viral infections.80–82 As the latter have 
been reviewed in depth recently,83 they will not be discussed 
further here. Although the above examples point clearly to 
a role for NLRP3 inflammasome activation in an array of 
human diseases, the involvement of this pathway in vari-
ous disease processes is far from straightforward, as most 
notably highlighted by a recent paper demonstrating that in 
colitis-associated cancer the NLRP3 inflammasome plays a 
protective role, with ASC-/- and caspase-1-/- mice showing 
increased disease severity and morbidity.84
The role of the NLRP3 
inflammasome in acute  
and chronic gout
Although the causal agent of gout has been understood 
for more than a century, the mechanisms underlying MSU 
crystal-induced inflammation have only recently begun to 
be unraveled. The pathological hallmark of a gout attack is 
considerable neutrophil influx into the synovium and joint 
fluid,3 however since neutrophils are absent in the normal 
joint the primary event following precipitation of MSU 
within the joint is believed to be the interaction of MSU 
crystals with resident joint cells, principally the synovial lin-
ing cells, which in turn trigger neutrophil ingress. Recent in 
vitro studies implicate mononuclear phagocytes as playing a 
central role in the initial response to MSU precipitation. The 
exposure of monocyte cell lines to MSU crystals leads to 
the production of proinflammatory cytokines, in particular 
IL-1β,85,86 and it is now understood that phagocytosis of MSU 
crystals is central to this process12 (Figure 2).  Following the 
recognition that MSU crystals may act as a ‘danger’ signal 
to cells in a similar way to microbial pathogens,87 Martinon 
et al demonstrated the NLRP3 inflammasome to be critical 
in sensing MSU deposition and subsequent activation of the 
downstream innate immune response.15 Macrophages from 
mice deficient in various components of the inflammasome, 
including caspase-1, ASC, and NLRP3, were unable to 
activate IL-1β in response to MSU stimulation. Notably, 
these mice also showed impaired neutrophil influx following 
intraperitoneal MSU injection, demonstrating the NLRP3 
 inflammasome as a critical link between the  well-established 
causal stimulus of gout and the subsequent pathological 
hallmark of an acute gout attack. Similar results were 
also demonstrated with CPPD crystals, the causal agent 
of pseudogout,  suggesting that similar mechanisms are 
involved in  regulating the inflammatory response in both 
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NADPH
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Figure 2 Inflammation in the gouty joint. Multiple steps in the inflammatory pathway are initiated by MSU deposition in the joint. MSU crystals are recognized by the 
pattern recognition receptors of the innate immune system, such as the TLRs and are phagocytosed by macrophages. Intracellular MSU crystals are recognized by the 
NLRP3 inflammasome (a multiprotein complex composed of a C-terminal LRR ‘sensor’ domain, a central nucleotide-binding domain (NACHT domain), which regulates self-
oligomerization and an N-terminal PYD) resulting in oligomerization of NLRP3 and cleavage of procaspase-1 to caspase-1. Cathepsin B, ROS, and K+ efflux (stimulated by 
ATP accumulation) are also understood to have some involvement in the activation and oligomerization of NLRP3 following MSU internalization. Caspase-1 in turn cleaves 
inactive proIL-1β, transcribed in a NF-κβ-dependent manner following TLR stimulation, to produce active IL-1β, which is released into the extracellular joint fluid. IL-1β 
activates IL1 receptors on endothelial cells and resident macrophages within the joint, resulting in signal transduction and gene activation and leading to the secretion of an 
array of proinflammatory cytokines and chemokines. These in turn recruit and activate leukocytes into the joint thereby amplifying the inflammatory cascade.
Abbreviations: ASC, apoptosis-associated speck-like protein containing a CARD; CARD, caspase recruitment domain; PYD, Pyrin domain; IL, interleukin; LRR, leucine-
rich repeat; MSU, monosodium urate; MyD88, myeloid differentiation primary response gene (88); NACHT, domain present in neuronal apoptosis inhibitor protein (NAIP) 
major histocompatibility complex class II transactivator; NF-κβ, nuclear factor κβ; NLRP, NACHT domain, LRR domain, and Pyrin domain-containing protein; ROS, reactive 
oxygen species; TLR, Toll-like receptor.
of these diseases. Despite much progress in elucidating the 
biological pathways coordinating a gout attack, the precise 
mechanisms by which endocytosed MSU crystals activate 
the NLRP3  inflammasome remain unclear and it is possible 
that sensing may occur through intermediary protein(s). 
Interestingly, the reduced severity of the inflammatory 
response triggered by CPPD deposition in pseudogout and 
the inflammasome neutrality of the chemically and struc-
turally similar allopurinol, suggests that subtle differences 
in the physical properties of different crystals, including 
surface charge and size, may be important in determining 
the intensity of the inflammatory response.
A recent study has shed light on the biologi-
cal mechanisms underlying the association between 
excessive consumption of food and onset of gout with the 
demonstration of a synergistic relationship between free 
fatty acids (FFA) and MSU for the activation of IL-1β.88 
In this study Joosten and colleagues demonstrated that 
MSU crystals alone were unable to induce IL-1β release 
from peripheral blood mononuclear cell (PBMC) isolated 
from healthy subjects; however in the presence of FFA, 
large amounts of active IL-1β were detected. Notably, 
IL-1β release in response to MSU and FFA injection was 
significantly reduced in caspase-1 and ASC deficient mice, 
but not in NLRP3 gene deficient mice.88 How these data fit 
with earlier studies indicating dependency on NLRP3 for 
MSU-induced IL-1β production is unclear and may point 
to the involvement of alternative inflammasome complexes 
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in the response to MSU or relate to differences in cell 
lineage, cell priming, and/or crystal structure between 
the studies.
In addition to the intracellular NLRP3 receptor, the 
extracellular TLR2 and TLR4 receptors may also play a 
role in the innate immune response to MSU deposition.89 
Macrophages isolated from TLR2-/- and TLR4-/- mice show 
impaired uptake of MSU crystals and reduced proinflam-
matory cytokine production, suggesting these TLRs to be 
essential for MSU crystal-induced inflammation.89 However 
conflicting results from a peritoneal model of acute gout 
suggest TLR2 and TLR4 to be dispensable in the immune 
response to MSU crystals.90 Nevertheless, as mentioned 
briefly above, it is conceivable that the contradictory results 
of these two studies may be attributable to cells in different 
tissues responding to MSU stimulation through different 
mechanisms. More recent studies now suggest that rather 
than having a role in the recognition of MSU crystals, the 
TLRs may play a more indirect part in responding to MSU 
deposition through regulation of the synthesis of pro-IL-1β 
(Figure 2).90,91
Together these studies allow a picture to be painted of 
our current understanding of the inflammatory process of an 
acute gout attack (Figure 2). During the initiation phase, MSU 
crystals precipitated within the joint stimulate extracellular 
TLR receptors expressed by resident monocytes, leading to 
transcription of pro-IL-1β. MSU crystals are also phagocy-
tosed by resident monocytes, an activity which is thought 
to be positively regulated by TLR activation,89 resulting in 
oligomerization of the NLRP3 inflammasome, activation of 
caspase-1, and subsequent cleavage of pro-IL-1β to produce 
active IL-1β. As discussed above, K+ efflux, ROS, and/
or cathepsin B may also be involved in mediating NLRP3 
activation. Following cleavage, active IL-1β is released by 
the resident monocytes and binds to IL-1 receptors expressed 
by endothelial cells and resident macrophages. During the 
‘amplification phase’ these cells respond to IL-1β by produc-
ing an array of proinflammatory cytokines and chemokines, 
which act together to coordinate the recruitment and activa-
tion of leukocytes into the joint.
One of the characteristic features of gout is that regard-
less of treatment, gout attacks are self-limiting. However, 
although great strides have been made in unraveling the 
molecular mechanisms of gout onset, our understanding of 
the mechanisms leading to resolution of a gout attack remain 
far less advanced. A range of possible mechanisms have 
been suggested, including the binding of crystals to inhibi-
tory proteins,92–94 maturation of monocytes to  macrophages, 
which express the anti-inflammatory TGF-β1 in response 
to MSU,95,96 and clearance of apoptotic leukocytes by 
macrophages.97,98 The balance between the multiple regula-
tory mechanisms that appear to be involved in mediating 
activation of the inflammasome pathway by MSU crystals, 
including ROS and K+ efflux, and inhibitors of the inflam-
masome pathway, including caspase-12 and CD4+ memory 
T-cells, may also be important in the down regulation of the 
inflammatory response that occurs during the resolution of 
an inflammatory gout attack.
Gout therapy has remained very much unchanged for 
the last 50 years. The British Society for Rheumatology 
recommends nonsteroidal anti-inflammatories (NSAIDs) 
as the first drug of choice for an acute gout attack, fol-
lowed by systemic or intra-articular glucocorticosteroids 
where NSAIDs are  contraindicated.99 The third line of 
treatment is oral colchicine, which is highly effective when 
given early in an acute gouty attack, but is poorly toler-
ated because of predictable gastrointestinal side effects. 
Notably, colchicine has been shown to suppress MSU 
crystal-induced NLRP3  inflammasome protein complex 
assembly, most likely through microtubule inhibition and 
subsequent impaired delivery of MSU crystals to the NLRP3 
 inflammatory protein complex in the cytosol, although this 
effect requires relatively high (micromolar) concentrations 
of colchicine.15 Recent animal model studies, using anakinra 
(an IL-1R antagonist) and mIL-1 Trap (an IL-1 inhibitor), 
clearly demonstrate the potential of targeting IL-1β for the 
management of MSU-induced inflammation.4,5 Moreover, 
early clinical studies of the IL-1 inhibitors, rilonacept (IL-1 
Trap),6 canakinumab (monoclonal anti-IL-1β antibody),9 
and anakinra,7,8,100 have demonstrated efficacy in the treat-
ment of patients with acute and chronic gout and have been 
generally well tolerated, although there are always concerns 
about increased incidence of infections when proinflam-
matory cytokines are inhibited and it should be noted that 
this has been observed in a subset of patients in a number 
of IL-1 inhibitor trials. These studies, coupled to in vitro 
evidence of the key role of the inflammasome pathway in 
activating IL-1β in gout, point to IL-1β and the upstream 
inflammasome regulatory pathways as key targets for the 
future treatment of gout.
Conclusions and implications  
for future research
Gout is the most common form of inflammatory arthritis in 
older men, affecting 1%–2% of adults in developed coun-
tries. Despite its prevalence, treatment options for gout have 
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remained static for almost half a century, with the approval 
of allopurinol in 1965 representing the last drug approved 
by the US Food and Drug Administration for treating gout. 
However, the last year has seen the approval of a new gout 
therapy, the xanthine oxidase inhibitor, febuxostat, and 
with several new drugs now in the late stages of clinical 
testing6,9,101 coupled with our enhanced level of understanding 
of the pathophysiology of the inflammatory process involved, 
we are entering a new era for the treatment of gout.
Although the precise molecular details of the NLRP3 inflam 
masome pathway and its response to MSU crystal deposition 
remain to be determined, the importance of inflammasomes 
and IL-1β activation to the pathology of gout is now firmly 
established. Notably, current strategies for targeting IL-1β 
have proved successful for alleviating the symptoms of gout 
in small clinical studies suggesting that targeting this and 
other components of the pathway may have an important 
place in gout and pseudogout treatment.6–9 Moreover, the 
impressive results of IL-1 inhibitors for the treatment of 
autoinflammatory syndromes confirm the potential of these 
agents for diseases such as gout, which involve excessive 
IL-1β production.
Despite significant advances in our understanding 
of the inflammatory processes involved in an acute gout 
attack, many questions remain to be addressed. The precise 
mechanism by which crystal recognition is achieved remains 
elusive, whilst the role of additional cytokines, which may 
be activated by the NLRP3 inflammasome, such as IL-18, 
must also be evaluated. Moreover, MSU may trigger other 
pathways aside from the NLRP3 inflammasome and it will 
be important to identify such pathways and understand their 
interaction with the NLRP3 inflammasome and IL-1β pro-
duction in the acute and resolution phases of gout. Answers 
to these questions will no doubt provide important insights 
into the mechanisms underlying MSU-induced inflamma-
tion and resolution, but may also reveal novel biologically 
relevant targets for the development of new, more effective 
therapeutic options for the treatment of gout.
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